# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $41 to $66.
Guggenheim analyst Debjit Chattopadhyay maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from...
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target fr...
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified e...
Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target...
HC Wainwright & Co. analyst Andrew Fein maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target ...
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0....
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...